scPharmaceuticals Inc. (SCPH) Performance Report

**Key Developments and Recent News:**

*   **Acquisition by MannKind Corporation:** On August 25, 2025, MannKind Corporation announced a definitive merger agreement to acquire scPharmaceuticals Inc. The deal is valued at up to $360 million, comprising an upfront cash payment of $5.35 per share and a Contingent Value Right (CVR) of up to $1.00 per share. This acquisition is anticipated to close in the fourth quarter of 2025. Following the announcement, several law firms initiated investigations regarding the fairness of the sale to scPharmaceuticals shareholders.
*   **Second Quarter 2025 Financial Results:** Announced on August 7, 2025, scPharmaceuticals reported net revenue of $16 million from its lead product, FUROSCIX, for the second quarter ended June 30, 2025. This represents a 99% increase year-over-year. The company filled approximately 20,200 FUROSCIX doses, marking a 117% increase from Q2 2024 and a 45% increase over Q1 2025. Despite revenue growth, scPharmaceuticals reported a net loss of $18.0 million for the quarter. Cash and cash equivalents stood at $40.8 million as of June 30, 2025.
*   **First Quarter 2025 Financial Results:** Reported on May 14, 2025, FUROSCIX generated $11.8 million in revenue, a 93% increase compared to the first quarter of 2024. The company filled approximately 13,900 FUROSCIX doses. A net loss of $19.7 million was reported for Q1 2025. As of March 31, 2025, cash and cash equivalents were $57.5 million.
*   **FUROSCIX Indication Expansion:** The U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) on March 6, 2025, expanding the FUROSCIX indication to include the treatment of edema in patients with chronic kidney disease (CKD). The formal launch of FUROSCIX for CKD occurred in April 2025.
*   **FUROSCIX Autoinjector (SCP-111) Progress:** The sNDA submission for the 80mg/1mL FUROSCIX Autoinjector (SCP-111), designed to reduce treatment time from five hours to under ten seconds, remains on track for the third quarter of 2025. Multiple U.S. patent applications covering SCP-111 received Notices of Allowance on August 14, 2025.
*   **Outlook and Pricing:** A 3.5% price increase for FUROSCIX became effective on July 1, 2025. The gross to net discount for FUROSCIX was approximately 27% in Q2 2025 and is anticipated to approach 30% in Q3 2025, primarily due to the implementation of the Medicare Part D redesign and mandatory manufacturer rebates under the Inflation Reduction Act. Management expects net cash outflows to decrease for the remainder of 2025 as revenues increase. The company also anticipates meaningful contributions from the nephrology market in Q3 and continued growth in prescription rates.